The small particle size of nano-crystalline suspension increases the bioavailability of water insoluble drug and facilitates their direct injection into the systemic circulation as particles. However, this small particle size can be responsible for their physical instability during storage and/or administration. The main challenges related to the production of nano-crystalline suspensions are to select the best stabilizer agent to ensure process-ability and to stabilize the API. Moreover, it is necessary to select the suitable technology for the suspension manufacturing taken into account the industrial constraints (scale-down/scale-up, process robustness and equipment reliability). The present thesis is focused on the formulation and the process development of nano-crystalline suspension. For the formulation part, we described a systematic approach to select optimum stabilizer for the preparation of nano-suspensions of given drug. The stabilizer can be either a dispersant or a combination of dispersant and wetting agents. The proposed screening method is a fast and efficient way to investigate a large number of stabilizers based on the principles of physical-chemistry and employs a stepwise approach. The methodology has been divided in two main parts; the first part focused on qualitative screening with the objective of selecting the appropriate candidate(s) for further investigations. The second part discussed quantitative screening with the objective of optimizing the ratio and the amount of wetting and dispersing agents. The results clearly showed that SDS/PVP as wetting/dispersing 40/60% (w/w) at a total concentration of 1.2% was the optimum stabilizer composition, at which the resulting nano-suspensions were stable at room temperature. Furthermore, the formulation robustness was assessed by measuring the rate of perikinetic, orthokinetic aggregation rate as a function of ionic strength (using NaCl), temperature and of pH variation. The results show that using the SDS/PVP mixture, the critical coagulation concentration is about five times higher than that observed in the literature for suspension colloidaly stable at high concentration. The nano-suspension was also found to be very stable at different pH conditions. Desorption test confirmed the high affinity between API and wetting/dispersing agent. However, the suspension undergoes aggregation at high temperature due to desorption of the wetting/dispersing agent and disaggregation of SDS micelles. Furthermore, aggregation occurs at very high shear rate by overcoming the energy barrier responsible for colloidal stability of the system. With respect to process engineering, a technological comparison (high pressure homogenization (HPH) versus bead milling) for the manufacturing of nano-suspension was carried out in terms of impact of suspension formulation, process parameters and technological configuration on the physical quality of the produced suspension. In addition both technologies were compared in terms of their robustness and their compliance to pharmaceutical regulations. The main findings are that, insofar the formulation is sufficiently robust and stable, both technologies are suitable for processing nano-crystalline suspensions. Bead milling is more powerful than HPH. It leads to a limit of milling (d50) lower than that obtained with HPH (100 vs 200 nm). In addition, for both technologies, one can observe that regardless, the process parameters used for milling and the scale, the relationship of d90 versus d50 could be described by a unique master curve (technology signature of milling pathway) outlining that the HPH leads to a tighten particle size distributions. Finally, a modelling approach based on adapted Tanka and Chodakov’s equation was proposed for modelling the milling kinetic. The generated model provides an accurate fit of milling kinetic, to predict and to simulate the milling manufacturing process.